Diagnocure appoints Chief Financial Officer



    Ticker Symbol: CUR

    QUEBEC CITY, Jan. 29 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a life
sciences company commercializing high-value cancer diagnostic tests and
delivering laboratory services, is pleased to announce the appointment of
Mr. Jean-François Bureau, CFA, as Chief Financial Officer.
    Mr. Bureau's experience spans over nearly twenty years in the North
American and European financial markets. Most recently, Mr. Bureau was Vice
President Credit - Specialized Products at National Bank of Canada, where he
was responsible for credit adjudication and led the implementation of credit
strategies. Prior to that, he held executive finance positions at a number of
companies, notably in the telecommunication sector. He was Vice President and
Financing Director within Le Groupe Vidéotron Ltée, where he raised over
US$400 million for U.S. expansion and led major M&A projects.
    Throughout his career, Mr. Bureau has been instrumental in ensuring sound
financing of companies at different stages of development in both Canada and
the United States.
    "We are very pleased that Jean-François Bureau, a top finance executive,
is joining us today", stated John Schafer, President and CEO of DiagnoCure.
"His wealth of experience in the financial market along with his North
American capital market expertise will be major assets in reaching our
corporate goals and strengthening our relationship with our investors and the
financial community."
    Born in Quebec City, Quebec, Mr. Bureau is a Chartered Financial Analyst
and holds a Bachelor in Business Administration from Laval University, and a
Master in Finance from Laval & York Universities.

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services that
increase clinician and patient confidence in making critical treatment
decisions. DiagnoCure is currently preparing to launch the Previstage(TM) GCC
Colorectal Cancer Staging Test, the first GCC-based molecular test for the
management of colorectal cancer. In 2003, the Company entered into a strategic
alliance with Gen-Probe (NASDAQ:   GPRO) for the development and
commercialization of a second-generation test for PCA3, DiagnoCure's
proprietary molecular marker highly specific to prostate cancer. The test is
now available through laboratories in the U.S. using PCA3 analyte specific
reagents (ASR) from Gen-Probe, and in Europe as the CE-marked PROGENSA(TM)
PCA3 in vitro assay. In addition to its own research, the Company intends to
acquire or in-license additional promising cancer biomarkers from both
academic and commercial institutions. For more information visit
www.diagnocure.com.

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.
    %SEDAR: 00003671EF




For further information:

For further information: John C. Schafer, President and Chief Executive
Officer, DiagnoCure Inc., (418) 527-6100; Paule De Blois, Vice President,
Corporate Affairs, DiagnoCure Inc., (418) 527-6100,
communications@diagnocure.com; Jean-Pierre Trudel, Jean-Pierre Trudel &
Associates, (514) 347-6111, jp.trudel@videotron.ca

Organization Profile

DiagnoCure Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890